PT  - JOURNAL ARTICLE
AU  - OKADA, TAKURO
AU  - MATSUKI, TAKASHI
AU  - FUSHIMI, CHIHIRO
AU  - OKAMOTO, ISAKU
AU  - SATO, HIROKI
AU  - KONDO, TAKAHITO
AU  - TOKASHIKI, KUNIHIKO
AU  - ITO, TATSUYA
AU  - MASUBUCHI, TATSUO
AU  - TADA, YUICHIRO
AU  - MIURA, KOUKI
AU  - HANYU, KENJI
AU  - OMURA, GO
AU  - TAKAHASHI, HIDEKI
AU  - YAMASHITA, TAKU
AU  - ORIDATE, NOBUHIKO
AU  - TSUKAHARA, KIYOAKI
TI  - Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
AID  - 10.21873/anticanres.15996
DP  - 2022 Oct 01
TA  - Anticancer Research
PG  - 4907--4912
VI  - 42
IP  - 10
4099  - http://ar.iiarjournals.org/content/42/10/4907.short
4100  - http://ar.iiarjournals.org/content/42/10/4907.full
SO  - Anticancer Res2022 Oct 01; 42
AB  - Background/Aim: Nivolumab has antitumor efficacy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who relapse within 6 months after platinum-based therapy; however, the efficacy of nivolumab for platinum-sensitive R/M HNSCC has not been shown. Therefore, this study compared the efficacy and safety of nivolumab for platinum-refractory and platinum-sensitive R/M HNSCC. Patients and Methods: This was a retrospective study of patients who received nivolumab for R/M HNSCC who had been previously treated with platinum-based anticancer drugs. Patients were divided into a platinum-sensitive and a platinum-refractory group, and progression-free survival (PFS), overall survival (OS), the overall response rate (ORR) [complete response (CR) + partial response (PR)], the disease control rate (DCR) (CR + PR + stable disease), and the incidence of immune-related adverse events (irAEs) were compared between the two groups. Results: We included 88 patients with squamous cell carcinoma: 60 with platinum-refractory disease and 28 with platinum-sensitive disease. The median PFS in the platinum-refractory and platinum-sensitive groups were 2.7 months and 5.3 months, respectively (p=0.03), and the median OS were 8.8 months and 17.1 months, respectively (p=0.06). There were no significant differences in the ORR, DCR, or incidence of irAEs between the two groups (p>0.99, p=0.11, and p>0.99, respectively). Conclusion: Nivolumab is a safe and effective treatment for platinum-sensitive R/M HNSCC.